MedTrace Logo

Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer

NCT02766582 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2024-02-26

Study results available
· View outcomes & findings →

Summary

Phase II single arm, open label, nonrandomized study. The aim of our study is to assess the Progression Free Survival (PFS) in suboptimally cytoreduced epithelial ovarian/ primary peritoneal/ fallopian tube cancer patients treated with the novel combination of carboplatin every 21 days (triweekly) /weekly paclitaxel IV with pembrolizumab IV followed by maintenance pembrolizumab IV.

Conditions

Interventions

DRUG

Pembrolizumab

IV every 21 days at 200 mg

DRUG

Carboplatin

IV every 21 days

DRUG

Paclitaxel

IV infusion (80mg/m2) every 7 days for 6 cycles

Sponsors & Collaborators

  • The Cleveland Clinic

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Denise Uyar, MD · Medical College of Wisconsin

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2022-05-31
Completion
2023-12-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02766582 on ClinicalTrials.gov